Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv. 2020;4(9):1824-1832.
Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL-mutation. Eur J Haematol. 2019.
Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.
GLCCI1 and GR genetic diversity and response to glucocorticoid-based treatment of graft-versus-host disease. Biol Blood Marrow Transplant. 2015.
Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2014..
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014.
High Number of memory T cells is associated with higher risk Of acute GVHD after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014..
Impact of acute and chronic Graft-vs-Host Disease on human B-cell generation and replication. Blood. 2014.
Late Donor Bone Marrow Failure After Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation. 2014;97(12):e75-e77..